We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Midatech Pharma Plc | LSE:MTPH | London | Ordinary Share | GB00BNGF1L75 | ORD GBP0.02 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 18.00 | 17.00 | 19.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMMTPH
RNS Number : 3774F
Midatech Pharma PLC
15 July 2021
15 July 2021
Midatech Pharma PLC
("Midatech" or the "Company")
Grant of Options
PDMR dealings
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines announces that options over a total of 1,924,000 ordinary shares of 0.1 pence each in the capital Company have been granted to employees under the 2014 Midatech Pharma plc Enterprise Management Incentive Scheme ("Options").
Of these Options, 750,000 in aggregate have been granted to two executives designated as PDMRs; Stephen Stamp, Chief Executive Officer, Chief Financial Officer and director of the Company and Dmitry Zamoryakhin, Chief Scientific Officer resulting in them having the following interests in the Company:
Director Award of Options Resulting interest Current shareholding in options in the Company Stephen Stamp - Chief Executive Officer, Chief Financial Officer 500,000 830,000 50,000 Dmitry Zamoryakhin - Chief Scientific Officer 250,000 250,000 -
The Options have an exercise price of 27.75 pence per share, being the mid-market closing price on 14 July 2021. The Options will vest 25% upon the one year anniversary of grant, with the remainder vesting in 12 equal tranches quarterly over the following three years. Once vested, the options will be exercisable until 14 June 2031.
The Options granted represent 1.95 per cent. of the issued share capital.
1 Details of the person discharging managerial responsibilities / person closely associated a) Name Stephen Stamp ------------------------------------- ---------------------------------------------- 2 Reason for the notification ------------------------------------------------------------------------------------- a) Position/status Chief Executive Officer, Chief Financial Officer ------------------------------------- ---------------------------------------------- b) Initial notification Initial notification /Amendment ------------------------------------- ---------------------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ------------------------------------------------------------------------------------- a) Name Midatech Pharma plc ------------------------------------- ---------------------------------------------- b) LEI 549300GKR2G40H3QFY57 ------------------------------------- ---------------------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ------------------------------------------------------------------------------------- a) Description of the Options over Ordinary shares of 0.1 financial instrument, pence each in Midatech Pharma plc type of instrument Identification code GB00BKT14T00 b) Nature of the transaction Grant of Options over Ordinary shares ------------------------------------- ---------------------------------------------- c) Price(s) and volume(s) --------------------- -------------------- Price(s) Volume(s) --------------------- -------------------- 27.75p 500,000 --------------------- -------------------- d) Aggregated information - Aggregated volume As above - Price e) Date of the transaction 15 June 2021 ------------------------------------- ---------------------------------------------- f) Place of the transaction Off market transaction ------------------------------------- ---------------------------------------------- 1 Details of the person discharging managerial responsibilities / person closely associated a) Name Dmitry Zamoryakhin ------------------------------------- ------------------------------------------- 2 Reason for the notification ---------------------------------------------------------------------------------- a) Position/status Chief Scientific Officer ------------------------------------- ------------------------------------------- b) Initial notification Initial notification /Amendment ------------------------------------- ------------------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ---------------------------------------------------------------------------------- a) Name Midatech Pharma plc ------------------------------------- ------------------------------------------- b) LEI 549300GKR2G40H3QFY57 ------------------------------------- ------------------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ---------------------------------------------------------------------------------- a) Description of the Options over Ordinary shares of 0.1 financial instrument, pence each in Midatech Pharma plc type of instrument Identification code GB00BKT14T00 b) Nature of the transaction Grant of Options over Ordinary shares ------------------------------------- ------------------------------------------- c) Price(s) and volume(s) ------------------- ------------------- Price(s) Volume(s) ------------------- ------------------- 27.75 p 250,000 ------------------- ------------------- d) Aggregated information - Aggregated volume As above - Price e) Date of the transaction 15 June 2021 ------------------------------------- ------------------------------------------- f) Place of the transaction Off market transaction ------------------------------------- -------------------------------------------
For more information, please contact:
Midatech Pharma PLC Stephen Stamp, CEO, CFO Tel: +44 (0)29 2048 0180 www.midatechpharma.com Panmure Gordon (UK) Limited (Nominated Adviser and Joint Broker) Freddy Crossley, Emma Earl (Corporate Finance) Rupert Dearden (Corporate Broking) Tel: +44 (0)20 7886 2500 Turner Pope Investments (TPI) Limited (Joint Broker) Andrew Thacker / James Pope (Corporate Broking) Tel: +44(0)20 3657 0050 IFC Advisory Limited (Financial PR and UK Investor Relations) Tim Metcalfe / Graham Herring Tel: +44 (0)20 3934 6630 Email: midatech@investor-focus.co.uk Edison Group (US Investor Relations) Maxwell Colbert Tel: +1 (646) 653 7028 Email: mcolbert @edisongroup.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHSFWSUIEFSEEW
(END) Dow Jones Newswires
July 15, 2021 05:28 ET (09:28 GMT)
1 Year Midatech Pharma Chart |
1 Month Midatech Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions